BFM
STLN

Boothbay Fund Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Boothbay Fund Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$423K Buy
137,792
+52,562
+62% +$161K 0.01% 1431
2025
Q4 		$303K Sell
85,230
-162,654
-66% -$603K ﹤0.01% 1422
2025
Q3 		$865K Buy
+247,884
New +$849K 0.01% 895

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's STLN Position: Q1 2026 in Review

Boothbay Fund Management increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 62% in Q1 2026, buying an estimated $161K and bringing the position to 137,792 shares worth $423K. The position accounts for 0.01% of the portfolio, ranked #1431.

Boothbay Fund Management first reported a position in STLN in Q3 2025 and has held it in 3 quarters since. The position peaked at $865K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Boothbay Fund Management held 137,792 shares of Starling Oncology Institute, Inc. Common Stock worth $423K as of Q1 2026.
  • Boothbay Fund Management bought 52,562 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $161K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1431 holding.
  • Boothbay Fund Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's Starling Oncology Institute, Inc. Common Stock position peaked at $865K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.